FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry. Disclosed is antibody bound with cell surface receptor DR5. Antibody exhibits cytotoxic activity against cells expressing containing domain death receptor, by means of apoptosis. Invention also relates to polynucleotide, vector, host cells for producing above antibody, as well as to pharmaceutical compositions and methods of treating and preventing malignant growth, autoimmune disease or inflammatory disease.
EFFECT: allows to intensify cytotoxic activity and DR5 antibodies inducing apoptosis in cells, as well as enables achieving effective therapeutic action in treating patient antibody according to invention.
44 cl, 58 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ANTI-DR5 ANTIBODY | 2011 |
|
RU2644678C1 |
| HUMANISED ANTI-AXL ANTIBODIES | 2010 |
|
RU2571224C2 |
| ANTI-B7-H3-ANTIBODY | 2012 |
|
RU2668170C2 |
| ANTIBODY SELECTIVE TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR, AND USES THEREOF | 2001 |
|
RU2298013C2 |
| Siglec-15 ANTIBODY | 2010 |
|
RU2539790C2 |
| ANTIBODY SELECTIVE TO RECEPTOR APOPTOSIS-INDUCING LIGAND AND ASSOCIATED WITH TUMOR NECROSIS FACTOR AND ITS USING | 2002 |
|
RU2313537C2 |
| COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
| DR5 ANTIBODIES AND USE THEREOF | 2006 |
|
RU2458072C2 |
| ANTIBODY TO EPHA2 | 2008 |
|
RU2525133C2 |
| ANTI-GARP ANTIBODY | 2016 |
|
RU2769379C2 |
